ClotBreaker Nanobots Dissolve Blood Clots Inside Bloodvessels — 5x More Effective Than IV Drugs
NanoClear's ClotBreaker nanobots successfully dissolved pulmonary artery clots in a pig model, using magnetic navigation to deliver clot-dissolving drugs directly at the blockage site. Clot-busting efficiency was 5x higher than conventional intravenous thrombolysis, with 80% less systemic bleeding risk.
Nanomedicine company NanoClear announced on April 8 that its ClotBreaker nanobot system achieved breakthrough results in pig-model experiments. ClotBreaker is a magnetic robot roughly 500 nanometers in diameter that navigates to a blood clot using an external magnetic field, then releases a concentrated dose of clot-dissolving medication at the site.
In the study, researchers created artificial clots in the pulmonary arteries of pigs, then injected ClotBreaker nanobots intravenously. Guided by magnetic fields, the robots reached the clot site within 20 minutes and released thrombolytic drugs at a local concentration 20 times higher than what conventional intravenous delivery achieves.
Results showed that ClotBreaker dissolved clots five times more efficiently than standard IV thrombolysis. Crucially, systemic bleeding risk dropped by 80% — because the drug is released only near the clot, leaving the body's overall coagulation system unaffected.
NanoClear plans to begin human clinical trials in 2031. If successful, ClotBreaker could fundamentally transform the treatment of deep vein thrombosis and pulmonary embolism.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.